GET DAILY SIGNALSDentsply Sirona (XRAY) Q3 Earnings: 7.5% Sales Decline and Guidance Cut Pressure Shares
Key Takeaways
- Net sales fell to $836 million, down 7.5% year over year (7% on a constant-currency basis) and below the roughly $859 million consensus estimate.
- Adjusted earnings per share (EPS) came in at $0.29, missing the $0.31 consensus and down from $0.37 in the prior-year quarter.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $146 million, a 17.5% margin, modestly beating the roughly $139 million consensus.
- GAAP (Generally Accepted Accounting Principles) net loss narrowed sharply to $2 million, or $0.01 per share, from a $427 million loss a year earlier, helped by the absence of a large goodwill impairment.
- Management cut its full-year 2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20–$1.30, down from the prior $1.40–$1.50 range.
- Shares fell roughly 14% immediately after the report, reflecting investor disappointment with the sales miss and guidance reduction.
- For more detail on the company, explore its Major News, Today's Price Move, Price Targets, and Forecast pages.
- You can also explore Trending AI Robots for additional data-driven market insights.
Why This Quarter Matters for the Turnaround Story
Dentsply Sirona stands as the largest diversified maker of professional dental products and technologies, and it is navigating a multi-year “Return-to-Growth” effort. The third-quarter results serve as an important checkpoint on that path. The company continues to face softer demand for dental equipment and implants, ongoing distributor destocking, and the ongoing wind-down of its Byte clear-aligner business. A top-line shortfall combined with a reduced full-year outlook gives investors a clearer picture of whether restructuring steps are taking hold or whether fresh challenges are emerging. The numbers also carry implications for the wider dental and medical-device space, where tariff exposure and uneven regional demand continue to influence results.
What the Numbers Showed
XRAY posted third-quarter 2026 net sales of $836 million, down 7.5% from $904 million a year earlier (7% on a constant-currency basis) and short of the roughly $859 million consensus. Adjusted EPS of $0.29 fell below the $0.31 consensus and the $0.37 reported in the same quarter last year. Adjusted EBITDA reached $146 million for a 17.5% margin, slightly ahead of the approximately $139 million consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
On a GAAP basis, the net loss narrowed to $2 million, or $0.01 per share, from the $427 million loss ($2.14 per share) recorded a year earlier. The prior period included a $262 million non-cash goodwill and intangible asset impairment. Gross margin rose to 52.9% from 48.8%, while the adjusted gross margin improved to 54.5% from 52.6%.
Management trimmed its full-year 2026 outlook to net sales of about $3.5 billion (versus the earlier $3.5–$3.6 billion range) and adjusted EPS of $1.20–$1.30, down from the previous $1.40–$1.50 range. The new EPS guidance excludes a $0.17 one-time tariff refund gain.
How Investors Reacted
Shares dropped roughly 14% right after the release. The move reflected disappointment over the revenue shortfall tied to continued softness in dental equipment and implants, along with the notable reduction in full-year revenue and adjusted EPS targets. Although the narrower GAAP loss and EBITDA beat provided some relief, the lowered guidance indicated that management expects headwinds to linger into the fourth quarter, which overshadowed the cost improvements seen in the quarter.
What to Watch Going Forward
Attention now turns to whether XRAY can stabilize sales in its most pressured segments. The Orthodontic and Implant Solutions business remains central, with the Byte wind-down still creating a year-over-year drag and premium implant volumes facing pressure in key markets. Progress with the value implant brand and any pickup in U.S. demand will be worth monitoring.
Cost control is another area to follow. The better gross margin points to restructuring benefits, yet the decision to lower guidance suggests management is favoring targeted investments over short-term earnings. Tracking how those investments translate into revenue growth will be important.
External elements such as tariffs, currency shifts, and distributor inventory levels also warrant attention. Further changes in trade policy or channel stocking patterns could affect both sales and margins in upcoming quarters. From what I see, these factors could shape the path through year-end.
Adding AI Tools to My Research Process
I often rely on Tickeron’s AI Screener when comparing companies like this one against peers. The platform helps filter stocks by technical patterns, fundamentals, and AI-driven signals, giving a structured way to identify trends and potential opportunities without manually combing through hundreds of names. It has become a regular part of my workflow for building context around quarterly results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
XRAY in upward trend: price rose above 50-day moving average on November 02, 2026
XRAY moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend. In 27 of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XRAY as a result. In 56 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for XRAY just turned positive on October 09, 2026. Looking at past instances where XRAY's MACD turned positive, the stock continued to rise in 31 of 53 cases over the following month. The odds of a continued upward trend are 58%.
Following a +2.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where XRAY advanced for three days, in 172 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XRAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
XRAY broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XRAY entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.489) is normal, around the industry mean (5.069). P/E Ratio (-3.696) is within average values for comparable stocks, (40.009). Projected Growth (PEG Ratio) (0.601) is also within normal values, averaging (4.143). XRAY's Dividend Yield (0.063) is considerably higher than the industry average of (0.005). P/S Ratio (0.557) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. XRAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XRAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a global denal eqipment company
Industry PharmaceuticalsOther
Advertisement